Cargando…

DOGS: Reaction-Driven de novo Design of Bioactive Compounds

We present a computational method for the reaction-based de novo design of drug-like molecules. The software DOGS (Design of Genuine Structures) features a ligand-based strategy for automated ‘in silico’ assembly of potentially novel bioactive compounds. The quality of the designed compounds is asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartenfeller, Markus, Zettl, Heiko, Walter, Miriam, Rupp, Matthias, Reisen, Felix, Proschak, Ewgenij, Weggen, Sascha, Stark, Holger, Schneider, Gisbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280956/
https://www.ncbi.nlm.nih.gov/pubmed/22359493
http://dx.doi.org/10.1371/journal.pcbi.1002380
_version_ 1782223887179710464
author Hartenfeller, Markus
Zettl, Heiko
Walter, Miriam
Rupp, Matthias
Reisen, Felix
Proschak, Ewgenij
Weggen, Sascha
Stark, Holger
Schneider, Gisbert
author_facet Hartenfeller, Markus
Zettl, Heiko
Walter, Miriam
Rupp, Matthias
Reisen, Felix
Proschak, Ewgenij
Weggen, Sascha
Stark, Holger
Schneider, Gisbert
author_sort Hartenfeller, Markus
collection PubMed
description We present a computational method for the reaction-based de novo design of drug-like molecules. The software DOGS (Design of Genuine Structures) features a ligand-based strategy for automated ‘in silico’ assembly of potentially novel bioactive compounds. The quality of the designed compounds is assessed by a graph kernel method measuring their similarity to known bioactive reference ligands in terms of structural and pharmacophoric features. We implemented a deterministic compound construction procedure that explicitly considers compound synthesizability, based on a compilation of 25'144 readily available synthetic building blocks and 58 established reaction principles. This enables the software to suggest a synthesis route for each designed compound. Two prospective case studies are presented together with details on the algorithm and its implementation. De novo designed ligand candidates for the human histamine H(4) receptor and γ-secretase were synthesized as suggested by the software. The computational approach proved to be suitable for scaffold-hopping from known ligands to novel chemotypes, and for generating bioactive molecules with drug-like properties.
format Online
Article
Text
id pubmed-3280956
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32809562012-02-22 DOGS: Reaction-Driven de novo Design of Bioactive Compounds Hartenfeller, Markus Zettl, Heiko Walter, Miriam Rupp, Matthias Reisen, Felix Proschak, Ewgenij Weggen, Sascha Stark, Holger Schneider, Gisbert PLoS Comput Biol Research Article We present a computational method for the reaction-based de novo design of drug-like molecules. The software DOGS (Design of Genuine Structures) features a ligand-based strategy for automated ‘in silico’ assembly of potentially novel bioactive compounds. The quality of the designed compounds is assessed by a graph kernel method measuring their similarity to known bioactive reference ligands in terms of structural and pharmacophoric features. We implemented a deterministic compound construction procedure that explicitly considers compound synthesizability, based on a compilation of 25'144 readily available synthetic building blocks and 58 established reaction principles. This enables the software to suggest a synthesis route for each designed compound. Two prospective case studies are presented together with details on the algorithm and its implementation. De novo designed ligand candidates for the human histamine H(4) receptor and γ-secretase were synthesized as suggested by the software. The computational approach proved to be suitable for scaffold-hopping from known ligands to novel chemotypes, and for generating bioactive molecules with drug-like properties. Public Library of Science 2012-02-16 /pmc/articles/PMC3280956/ /pubmed/22359493 http://dx.doi.org/10.1371/journal.pcbi.1002380 Text en Hartenfeller et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Hartenfeller, Markus
Zettl, Heiko
Walter, Miriam
Rupp, Matthias
Reisen, Felix
Proschak, Ewgenij
Weggen, Sascha
Stark, Holger
Schneider, Gisbert
DOGS: Reaction-Driven de novo Design of Bioactive Compounds
title DOGS: Reaction-Driven de novo Design of Bioactive Compounds
title_full DOGS: Reaction-Driven de novo Design of Bioactive Compounds
title_fullStr DOGS: Reaction-Driven de novo Design of Bioactive Compounds
title_full_unstemmed DOGS: Reaction-Driven de novo Design of Bioactive Compounds
title_short DOGS: Reaction-Driven de novo Design of Bioactive Compounds
title_sort dogs: reaction-driven de novo design of bioactive compounds
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280956/
https://www.ncbi.nlm.nih.gov/pubmed/22359493
http://dx.doi.org/10.1371/journal.pcbi.1002380
work_keys_str_mv AT hartenfellermarkus dogsreactiondrivendenovodesignofbioactivecompounds
AT zettlheiko dogsreactiondrivendenovodesignofbioactivecompounds
AT waltermiriam dogsreactiondrivendenovodesignofbioactivecompounds
AT ruppmatthias dogsreactiondrivendenovodesignofbioactivecompounds
AT reisenfelix dogsreactiondrivendenovodesignofbioactivecompounds
AT proschakewgenij dogsreactiondrivendenovodesignofbioactivecompounds
AT weggensascha dogsreactiondrivendenovodesignofbioactivecompounds
AT starkholger dogsreactiondrivendenovodesignofbioactivecompounds
AT schneidergisbert dogsreactiondrivendenovodesignofbioactivecompounds